Evidence map›Paper›PMID 34835882›Full record

ReviewNanomaterials (Basel, Switzerland)2021

Metal Nanoparticles against Viruses: Possibilities to Fight SARS-CoV-2.

Marcelly Chue-Gonçalves, Giovana N Pereira, Lígia C Faccin-Galhardi, Renata K T Kobayashi, Gerson Nakazato

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Tailoring biomaterials for vaccine delivery.Journal of nanobiotechnology · 2024
    Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marcelly Chue-GonçalvesLaboratory of Basic and Applied Bacteriology, Department of Microbiology, Biological Sciences Center, Londrina State University, Londrina 86057-970, Brazil.ORCID 0000-0003-0949-9795
Giovana N PereiraLaboratory of Basic and Applied Bacteriology, Department of Microbiology, Biological Sciences Center, Londrina State University, Londrina 86057-970, Brazil.
Lígia C Faccin-GalhardiLaboratory of Virology, Department of Microbiology, Biological Sciences Center, Londrina State University, Londrina 86057-970, Brazil.
Renata K T KobayashiLaboratory of Basic and Applied Bacteriology, Department of Microbiology, Biological Sciences Center, Londrina State University, Londrina 86057-970, Brazil.ORCID 0000-0001-7170-2155
Gerson NakazatoLaboratory of Basic and Applied Bacteriology, Department of Microbiology, Biological Sciences Center, Londrina State University, Londrina 86057-970, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In view of the current Coronavirus Disease 2019 (COVID-19) pandemic outbreak, the research community is focusing on development of diagnostics, treatment, and vaccines to halt or reverse this scenario. Although there are already various vaccines available, adaptive mutations in the SARS-CoV-2 genome can alter its pathogenic potential and, at the same time, increase the difficulty of developing drugs or immunization by vaccines. Nanotechnology carries a potential to act in all stages in fighting this viral disease, with several possibilities of strategies such as applying nanoparticles directly as antivirals in delivery systems against these viruses or incorporating them in materials, with power of achievement in therapeutics, vaccines and prevention. In this paper, we review and bring insights of recent studies using metal nanocomposites as antivirals against coronavirus and structurally similar viruses.

Indexed as

antiviralcoronavirusCOVID-19nanoparticlespersonal protective equipmentSARS-CoV-2

Identifiers

PMID34835882
PMCPMC8618109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.